Arecor Therapeutics plc (AIM:AREC)

Market Cap	30.21M
Revenue (ttm)	5.06M
Net Income (ttm)	-8.10M
Shares Out	37.76M
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,412
Average Volume	42,633
Open	81.50
Previous Close	80.00
Day's Range	81.40 - 81.50
52-Week Range	35.40 - 100.00
Beta	-0.29
RSI	76.61
Earnings Date	Dec 24, 2025

About Arecor Therapeutics

Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 44
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AREC

Financial Performance

In 2024, Arecor Therapeutics's revenue was 5.05 million, an increase of 10.50% compared to the previous year's 4.57 million. Losses were -10.24 million, 19.7% more than in 2023.